Comment
doi: 10.1016/S1470-2045(22)00449-1.
Epub 2022 Jul 28.
Combination regimens in EGFR-mutated lung cancer: can we get ORIENT-ed?
Affiliations
- PMID: 35908559
- DOI: 10.1016/S1470-2045(22)00449-1
Item in Clipboard
Comment
Combination regimens in EGFR-mutated lung cancer: can we get ORIENT-ed?
Lancet Oncol.
2022 Sep.
No abstract available
Conflict of interest statement
AE reports funding from the Canadian Institutes of Health Research, the Royal College of Surgeons and Physicians of Canada, and the Henry R Shibata Research Fellowship. HY has consulted for Daiichi, Janssen, AstraZeneca, Black Diamond, Blueprint, and Cullinan; and reports research funding from Daiichi, Janssen, AstraZeneca, Black Diamond, Blueprint, Novartis, Pfizer, Cullinan, and ERASCA.
Comment on
-
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.Lancet Oncol. 2022 Sep;23(9):1167-1179. doi: 10.1016/S1470-2045(22)00382-5. Epub 2022 Jul 28. Lancet Oncol. 2022. PMID: 35908558 Clinical Trial.
Similar articles
-
Cardiac Toxicity From Afatinib in EGFR-Mutated NSCLC: A Rare But Possible Side Effect.J Thorac Oncol. 2019 Jul;14(7):e145-e146. doi: 10.1016/j.jtho.2019.02.027. J Thorac Oncol. 2019. PMID: 31235038 No abstract available.
-
Combination Therapy for EGFR-Mutated Lung Cancer.N Engl J Med. 2023 Nov 23;389(21):2005-2007. doi: 10.1056/NEJMe2311559. Epub 2023 Nov 8. N Engl J Med. 2023. PMID: 37937797 No abstract available.
-
Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer.Proc Jpn Acad Ser B Phys Biol Sci. 2020;96(7):266-272. doi: 10.2183/pjab.96.020. Proc Jpn Acad Ser B Phys Biol Sci. 2020. PMID: 32788550 Free PMC article. Review.
-
Re-ORIENT-ing antitumor immunity in EGFR-mutant non-small cell lung cancer: are antiangiogenics the key?Chin Clin Oncol. 2023 Jun;12(3):31. doi: 10.21037/cco-23-28. Epub 2023 Apr 25. Chin Clin Oncol. 2023. PMID: 37164932 No abstract available.
-
Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?Med Oncol. 2014 Aug;31(8):78. doi: 10.1007/s12032-014-0078-5. Epub 2014 Jun 24. Med Oncol. 2014. PMID: 24958518 Review.
Cited by
-
The Efficiency and Safety of Triple-Drug Combination of Albumin-Bound Paclitaxel, Anlotinib and PD-1/L1 Inhibitors in the 2nd or Above Line of Advanced NSCLC: A Retrospective Cohort Study.Cancer Manag Res. 2024 Aug 8;16:1003-1012. doi: 10.2147/CMAR.S472196. eCollection 2024. Cancer Manag Res. 2024. PMID: 39135711 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
